Moreover, although a slight rise of sPD-L1 was observed in our experimental setting analyzing cancer patients treated with anti-CTLA-4 and anti-PD-1, these levels were not comparable with the stronger increases observed in anti-PD-L1-treated patients. Here, CTLA4 is linked to cancer.